News

Deal Announcements

Bluebird Bio Bags $30 Million Third VC Funding

Thursday, April 21, 2011 5:54:00 AM PDT | VentureDeal Staff
   Cambridge, Massachusetts  --  Genetic therapy company Bluebird Bio has secured $30 million in its series C round of venture capital financing.

Bluebird has developed a gene therapy platform for novel treatments for diseases with few or no clinical options.

Investors in the round included ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital.

The company said it would use the funding to move forward on its clinical trial program and invest in its core product platform capabilities.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1